KKR has invested $400 million to acquire a controlling stake in HCG, India's leading oncology provider, to enhance healthcare delivery in the region.
Target Information
HCG, or Healthcare Global Enterprises Ltd., is one of India’s most prominent oncology service providers, recognized for its pioneering efforts in cancer care over the past three decades. With a robust network of 25 oncology centers spread across 19 cities, HCG has positioned itself as a crucial player in India’s healthcare landscape, offering advanced treatment options and innovative care solutions to patients.
The company boasts impressive facilities including nearly 2,500 hospital beds, approximately 100 operating theatres, and 40 Linear Accelerator (LINAC) machines, which are essential for delivering high-quality cancer treatments. Post the investment, HCG aims to further expand its reach and enhance its clinical services.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in India
India's healthcare industry has undergone significant transformation in recent years, driven by increasing demand for healthcare services and investment from both domestic and international entities. The oncology sector, in particular, has seen s
Similar Deals
KKR → Healthcare Global Enterprises (HCG)
2023
Eris Lifesciences → Biocon Biologics Limited - Dermatology and Nephrology Business Units
2023
KKR
invested in
HCG
in 2023
in a Buyout deal
Disclosed details
Transaction Size: $400M